Last reviewed · How we verify
Pegylated Interferon-alpha2a — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Pegylated Interferon-alpha2a (Pegylated Interferon-alpha2a) — Seoul National University Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pegylated Interferon-alpha2a TARGET | Pegylated Interferon-alpha2a | Seoul National University Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pegylated Interferon-alpha2a CI watch — RSS
- Pegylated Interferon-alpha2a CI watch — Atom
- Pegylated Interferon-alpha2a CI watch — JSON
- Pegylated Interferon-alpha2a alone — RSS
Cite this brief
Drug Landscape (2026). Pegylated Interferon-alpha2a — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-interferon-alpha2a. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing